pioglitazone has been researched along with Left Ventricular Hypertrophy in 11 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Long-term administration of pioglitazone attenuated left ventricular hypertrophy and fibrosis as well as inhibited phosphorylation of mammalian target of rapamycin and p70S6 kinase in the heart of hypertensive rats." | 7.74 | Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. ( Cheng, XW; Kato, MF; Koike, Y; Miyachi, M; Murate, T; Murohara, T; Nagata, K; Nishizawa, T; Noda, A; Obata, K; Shibata, R; Tsuboi, K; Yamada, T; Yazawa, H; Yokota, M, 2008) |
| "We investigated the long-term effects of the thiazolidinedione PPARgamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats (SHRSP), a model of malignant of hypertension." | 7.72 | Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats. ( Amiri, F; Benkirane, K; Diep, QN; Paradis, P; Schiffrin, EL, 2004) |
| "Sustained left ventricular hypertrophy (LVH) accelerates cardiac dysfunction and heart failure." | 5.36 | Activation of PPARgamma by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats. ( Bekeredjian, R; Buss, SJ; Hagenmüller, M; Hardt, SE; Katus, HA; Münz, S; Ochs, M; Pichler, M; Weiss, CS, 2010) |
| "Long-term administration of pioglitazone attenuated left ventricular hypertrophy and fibrosis as well as inhibited phosphorylation of mammalian target of rapamycin and p70S6 kinase in the heart of hypertensive rats." | 3.74 | Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. ( Cheng, XW; Kato, MF; Koike, Y; Miyachi, M; Murate, T; Murohara, T; Nagata, K; Nishizawa, T; Noda, A; Obata, K; Shibata, R; Tsuboi, K; Yamada, T; Yazawa, H; Yokota, M, 2008) |
| "We investigated the long-term effects of the thiazolidinedione PPARgamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats (SHRSP), a model of malignant of hypertension." | 3.72 | Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats. ( Amiri, F; Benkirane, K; Diep, QN; Paradis, P; Schiffrin, EL, 2004) |
| "Telmisartan is an angiotensin II receptor blocker, which acts as a partial agonist of peroxisome proliferator activator receptor-γ (PPAR-γ)." | 1.38 | Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia. ( Hirata, Y; Hishikari, K; Isobe, M; Masumura, M; Nagai, R; Nagashima, A; Ogawa, M; Shimizu, T; Suzuki, J; Takayama, K; Watanabe, R, 2012) |
| "Sustained left ventricular hypertrophy (LVH) accelerates cardiac dysfunction and heart failure." | 1.36 | Activation of PPARgamma by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats. ( Bekeredjian, R; Buss, SJ; Hagenmüller, M; Hardt, SE; Katus, HA; Münz, S; Ochs, M; Pichler, M; Weiss, CS, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, MF | 1 |
| Shibata, R | 1 |
| Obata, K | 1 |
| Miyachi, M | 1 |
| Yazawa, H | 1 |
| Tsuboi, K | 1 |
| Yamada, T | 1 |
| Nishizawa, T | 1 |
| Noda, A | 1 |
| Cheng, XW | 1 |
| Murate, T | 1 |
| Koike, Y | 1 |
| Murohara, T | 1 |
| Yokota, M | 1 |
| Nagata, K | 1 |
| Weiss, CS | 1 |
| Hagenmüller, M | 1 |
| Pichler, M | 1 |
| Münz, S | 1 |
| Ochs, M | 1 |
| Buss, SJ | 1 |
| Bekeredjian, R | 1 |
| Katus, HA | 1 |
| Hardt, SE | 1 |
| Ye, Y | 1 |
| Keyes, KT | 1 |
| Zhang, C | 1 |
| Perez-Polo, JR | 1 |
| Lin, Y | 1 |
| Birnbaum, Y | 1 |
| Tian, YQ | 1 |
| Li, SS | 1 |
| Su, XD | 1 |
| Zhang, GZ | 1 |
| Zhao, JJ | 1 |
| Li, GW | 1 |
| Wang, L | 1 |
| Nagashima, A | 1 |
| Watanabe, R | 1 |
| Ogawa, M | 1 |
| Suzuki, J | 1 |
| Masumura, M | 1 |
| Hishikari, K | 1 |
| Shimizu, T | 1 |
| Takayama, K | 1 |
| Hirata, Y | 1 |
| Nagai, R | 1 |
| Isobe, M | 1 |
| Diep, QN | 1 |
| Amiri, F | 1 |
| Benkirane, K | 1 |
| Paradis, P | 1 |
| Schiffrin, EL | 1 |
| Gaillard, V | 2 |
| Casellas, D | 1 |
| Seguin-Devaux, C | 1 |
| Schohn, H | 1 |
| Dauça, M | 2 |
| Atkinson, J | 2 |
| Lartaud, I | 2 |
| Ledingham, JM | 1 |
| Laverty, R | 1 |
| Shinzato, T | 2 |
| Ohya, Y | 2 |
| Nakamoto, M | 2 |
| Ishida, A | 1 |
| Takishita, S | 2 |
| Mano, R | 1 |
| Yamazato, M | 1 |
| Sakima, A | 1 |
11 other studies available for pioglitazone and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Atrial Natriuretic Factor; Collagen; Echocardio | 2008 |
Activation of PPARgamma by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats.
Topics: Animals; Aorta, Thoracic; Atrial Natriuretic Factor; Disease Models, Animal; Echocardiography; Hyper | 2010 |
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.
Topics: Animals; Blood Glucose; Blotting, Western; Body Weight; Culture Media; Cyclic AMP; Cyclic AMP-Depend | 2010 |
Effects of pioglitazone on high-fat-diet-induced ventricular remodeling and dysfunction in rats.
Topics: Animals; Blood Pressure; Diet, High-Fat; Echocardiography; Fatty Acids, Nonesterified; Hypertrophy, | 2012 |
Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antihypertensive Agents; Ben | 2012 |
Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Hypertension; Hypertrophy, Left Ventricular; Male; Myocarditis; Pioglitazone; PPAR gamma; R | 2004 |
Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis.
Topics: Animals; Aorta; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Blood Pressure; Calcinosis; Cyto | 2005 |
Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Basilar Artery; Blood Pressure; Disease Models, An | 2005 |
[Pioglitazone protects against elastocalcinosis and improves aortic wall elasticity].
Topics: Animals; Aorta; Arteries; Calcinosis; Elasticity; Hypertrophy, Left Ventricular; Hypoglycemic Agents | 2007 |
Beneficial effects of pioglitazone on left ventricular hypertrophy in genetically hypertensive rats.
Topics: Animals; Blood Glucose; Blood Pressure; Collagen Type I; Collagen Type III; Connective Tissue Growth | 2007 |
Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Fibrosis; Hypertension; Hypertrophy, Lef | 2008 |